The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
What is the impact of belantamab mafodotin on QoL in patients with MM?
Featured:
Vania Tietsche de Moraes Hungria
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 1
Which of the following strategies was effective at managing ocular toxicities associated with belantamab mafodotin in the phase III DREAMM-7 trial?
A
B
C
D
The Multiple Myeloma Hub spoke to Vania Tietsche de Moraes Hungria, Clínica São Germano, São Paolo, BR. We asked, What is the impact of belantamab mafodotin (belamaf) on quality of life (QoL) in patients with multiple myeloma (MM)?
What is the impact of belantamab mafodotin on QoL in patients with MM?
Hungria provided insights into the mechanism of action of belamaf, its efficacy and safety in heavily pre-treated patients, and the latest findings from the phase III DREAMM-7 (NCT04246047) study. Hungria discussed how belamaf in combination with bortezomib and dexamethasone (BelaVd) impacts disease progression, survival, and patient-reported outcomes compared to daratumumab with Vd (DaraVd). This discussion also evaluated the safety profile of belamaf, including ocular side effects and their impact on QoL.
Key learnings
- Belamaf is an antibody–drug conjugate that targets the B-cell maturation antigen on malignant plasma cells.
- Belamaf has previously demonstrated promising anti-myeloma activity and a manageable safety profile as a sole agent in patients with heavily pre-treated MM.
DREAMM-71,2
- DREAMM-7 is a phase III, randomized study evaluating BelaVd vs DaraVd in patients with relapsed/refractory MM.
- A statistically significant benefit in progression-free survival, overall survival, duration of response, and measurable residual disease negativity were observed with BelaVd.
- Patients reported stable quality of life, physical functioning, fatigue, and disease symptoms, with no significant differences between treatment arms.
- Ocular toxicities were more common during the initial phase of treatment but generally improved as dosing frequency was reduced, highlighting dose modification as an effective strategy to manage these effects.
- Among patients who experienced a clinically meaningful decline in visual acuity, overall QoL remained comparable to those treated with DaraVd.
- BelaVd has a limited impact on health-related QoL, supporting its potential as a new standard of care treatment for relapsed/refractory MM.
This educational resource is independently supported by GSK. All content was developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
